Skip to main content

Table 1 Identification of potential HLA-A2.1-restricted CTL epitopes from ECM1

From: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Epitope Start End Length Sequence IC50 (nM)a S valueb
NP 168 176 9 PPGRPSPDN 46,882.04 − 11.09
KA 90 98 9 KLLPAQLPA 15 − 36.26
YV 488 496 9 YLSPGDEQV 18.15 − 34.22
IV 409 417 9 ILTIDISRV 102.40 − 38.65
AV 8 16 9 ALVLTYLAV 174.81 − 39.46
YL 43 51 9 YAAPPSPPL 267.8 − 40.34
LA 9 17 9 LVLTYLAVA 334.48 − 42.45
QP 86 94 9 LQQEKLLPA 392.06 − 41.10
  1. aIC50, the half maximal inhibitory concentration, obtained from IEDB, IC50 < 500 nM
  2. bS value, the free-energy between docking molecules calculated by MOE